Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Associates in Women's Health
mi
from
Wichita, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Associates in Women's Health
mi
from
Wichita, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Via Christi Regional Medical Center
mi
from
Wichita, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center- Fairlane
mi
from
Dearborn, MI
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center- Fairlane
mi
from
Dearborn, MI
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center-Columbus
mi
from
Novi, MI
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center-Columbus
mi
from
Novi, MI
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Strecker Cancer Center-Belpre
mi
from
Belpre, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Strecker Cancer Center-Belpre
mi
from
Belpre, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Miami Valley South
mi
from
Centerville, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Miami Valley South
mi
from
Centerville, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Adena Regional Medical Center
mi
from
Chillicothe, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Adena Regional Medical Center
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc - Kenwood
mi
from
Cincinnati, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc - Kenwood
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Mount Carmel East Hospital
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Mount Carmel East Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Columbus Oncology and Hematology Associates Inc
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Columbus Oncology and Hematology Associates Inc
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Grant Medical Center
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Grant Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Mount Carmel Health Center West
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Doctors Hospital
mi
from
Columbus, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Doctors Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Samaritan North
mi
from
Dayton, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Samaritan North
mi
from
Dayton, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Delaware Health Center-Grady Cancer Center
mi
from
Delaware, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Delaware Health Center-Grady Cancer Center
mi
from
Delaware, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Delaware Radiation Oncology
mi
from
Delaware, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Delaware Radiation Oncology
mi
from
Delaware, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Grady Memorial Hospital
mi
from
Delaware, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Grady Memorial Hospital
mi
from
Delaware, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Armes Family Cancer Center
mi
from
Findlay, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Armes Family Cancer Center
mi
from
Findlay, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Blanchard Valley Hospital
mi
from
Findlay, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Orion Cancer Care
mi
from
Findlay, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Orion Cancer Care
mi
from
Findlay, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Atrium
mi
from
Franklin, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Wayne
mi
from
Greenville, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Wayne
mi
from
Greenville, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Wayne Hospital
mi
from
Greenville, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Wayne Hospital
mi
from
Greenville, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greater Dayton Cancer Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Fairfield Medical Center
mi
from
Lancaster, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Fairfield Medical Center
mi
from
Lancaster, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Marietta Memorial Hospital
mi
from
Marietta, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Marietta Memorial Hospital
mi
from
Marietta, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dayton Physicians LLC-Signal Point
mi
from
Middletown, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dayton Physicians LLC-Signal Point
mi
from
Middletown, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Knox Community Hospital
mi
from
Mount Vernon, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Knox Community Hospital
mi
from
Mount Vernon, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Licking Memorial Hospital
mi
from
Newark, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Licking Memorial Hospital
mi
from
Newark, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Newark Radiation Oncology
mi
from
Newark, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Newark Radiation Oncology
mi
from
Newark, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Click here to add this to my saved trials